The irony is that the same payers resisting broad access on cost grounds are also failing to invest in the outcomes tracking architecture that would let them evaluate whether their cost concerns are justified
District Judge Karen Marston in the Eastern District of Pennsylvania, following the unexpected passing of U.S
GLP-1s may possibly enhance synaptic dopamine levels
But I dont believe thats been studied in a rigorous way. Rather than developing a dosage off-ramp, other experts argue that these drugs should be treated like any other chronic disease medication
This mechanism increases IGF-1, supporting muscle regeneration, fat metabolism, and tissue repair
That means cool temperatures (around 65F), blackout curtains, and screen-free wind-down time